ADMA Biologics' Aseptic Fill-Finish Machine Scores FDA Approval

The FDA has approved ADMA Biologics Inc's ADMA in-house aseptic fill-finish machine, the VanRx SA25.
Related Content: ADMA Biologics Stock Gains On FDA Approval For Plasma Collection Facility.
With the VanRx operational, the Company expects a meaningful improvement in gross margins, enhanced patient supply consistency, accelerated inventory production cycle times, and increased control and visibility of commercial product lot releases.
The approval of the VanRx will also provide ADMA with the opportunity to onboard new fill-finish contract manufacturing opportunities with third parties.
The VanRx fill-finish machine utilizes a closed isolator design that removes human interventions and provides safe drug products for patients.
Related content: Benzinga's Full FDA Calendar.
Price Action: ADMA shares are up 10.2% at $1.40 during the premarket session on the last check Wednesday.

Momentum92.65

GrowthNot Available

QualityNot Available

Value21.06

Short

Medium

Long